ID   PC9-OR3
AC   CVCL_D7FI
RX   PubMed=31555510;
CC   Population: Chinese; Han and Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:90943; Osimertinib (AZD9291).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   PubMed=31555510; DOI=10.21037/tlcr.2019.08.22; PMCID=PMC6749116;
RA   Codony-Servat J., Viteri S., Codony-Servat C., Ito M., Bracht J.W.P.,
RA   Berenguer J., Chaib I., Molina-Vila M.A., Karachaliou N., Rosell R.;
RT   "Hsp90 inhibitors enhance the antitumoral effect of osimertinib in
RT   parental and osimertinib-resistant non-small cell lung cancer cell
RT   lines.";
RL   Transl. Lung Cancer Res. 8:340-351(2019).
//